75 related articles for article (PubMed ID: 21222362)
21. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways.
Leibowitz-Amit R; Tsarfaty G; Abargil Y; Yerushalmi GM; Horev J; Tsarfaty I
Cancer Res; 2006 Sep; 66(17):8687-97. PubMed ID: 16951184
[TBL] [Abstract][Full Text] [Related]
22. Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells.
Veiga E; Cossart P
Nat Cell Biol; 2005 Sep; 7(9):894-900. PubMed ID: 16113677
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.
Watson GA; Zhang X; Stang MT; Levy RM; Queiroz de Oliveira PE; Gooding WE; Christensen JG; Hughes SJ
Neoplasia; 2006 Nov; 8(11):949-55. PubMed ID: 17132227
[TBL] [Abstract][Full Text] [Related]
24. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.
Shinomiya N; Gao CF; Xie Q; Gustafson M; Waters DJ; Zhang YW; Vande Woude GF
Cancer Res; 2004 Nov; 64(21):7962-70. PubMed ID: 15520203
[TBL] [Abstract][Full Text] [Related]
25. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
26. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
[TBL] [Abstract][Full Text] [Related]
27. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.
Humbert M; Medová M; Aebersold DM; Blaukat A; Bladt F; Fey MF; Zimmer Y; Tschan MP
Biochem Biophys Res Commun; 2013 Feb; 431(2):264-9. PubMed ID: 23313490
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
[TBL] [Abstract][Full Text] [Related]
29. Met-driven invasive growth involves transcriptional regulation of Arhgap12.
Gentile A; D'Alessandro L; Lazzari L; Martinoglio B; Bertotti A; Mira A; Lanzetti L; Comoglio PM; Medico E
Oncogene; 2008 Sep; 27(42):5590-8. PubMed ID: 18504429
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
31. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met.
Petrelli A; Gilestro GF; Lanzardo S; Comoglio PM; Migone N; Giordano S
Nature; 2002 Mar; 416(6877):187-90. PubMed ID: 11894096
[TBL] [Abstract][Full Text] [Related]
32. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
Lutterbach B; Zeng Q; Davis LJ; Hatch H; Hang G; Kohl NE; Gibbs JB; Pan BS
Cancer Res; 2007 Mar; 67(5):2081-8. PubMed ID: 17332337
[TBL] [Abstract][Full Text] [Related]
33. A direct role for Met endocytosis in tumorigenesis.
Joffre C; Barrow R; Ménard L; Calleja V; Hart IR; Kermorgant S
Nat Cell Biol; 2011 Jun; 13(7):827-37. PubMed ID: 21642981
[TBL] [Abstract][Full Text] [Related]
34. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
[TBL] [Abstract][Full Text] [Related]
35. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
[TBL] [Abstract][Full Text] [Related]
36. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
Moore AE; Greenhough A; Roberts HR; Hicks DJ; Patsos HA; Williams AC; Paraskeva C
Carcinogenesis; 2009 Oct; 30(10):1796-804. PubMed ID: 19638428
[TBL] [Abstract][Full Text] [Related]
37. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Uhland K; Siphos B; Arkona C; Schuster M; Petri B; Steinmetzer P; Mueller F; Schweinitz A; Steinmetzer T; Van De Locht A
Int J Oncol; 2009 Aug; 35(2):347-57. PubMed ID: 19578749
[TBL] [Abstract][Full Text] [Related]
38. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability.
Nam HJ; Chae S; Jang SH; Cho H; Lee JH
Carcinogenesis; 2010 Sep; 31(9):1531-40. PubMed ID: 20584748
[TBL] [Abstract][Full Text] [Related]
39. Induction of met proto-oncogene (hepatocyte growth factor receptor) expression during human monocyte-macrophage differentiation.
Chen Q; DeFrances MC; Zarnegar R
Cell Growth Differ; 1996 Jun; 7(6):821-32. PubMed ID: 8780895
[TBL] [Abstract][Full Text] [Related]
40. Met receptor dynamics and signalling.
Hammond DE; Carter S; Clague MJ
Curr Top Microbiol Immunol; 2004; 286():21-44. PubMed ID: 15645709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
